[(Name of Issuer) Common Stock 16938C106 (CUSIP Number) October 28, 2015 (Date of Event Which Requires Filing of this Statement) ☐ Rule 13d-1(b) ☑ Rule 13d-1(c) ☐ Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent]
[(Name of Issuer) Common Stock 16938C106 (CUSIP Number) October 28, 2015 (Date of Event Which Requires Filing of this Statement) ☐ Rule 13d-1(b) ☑ Rule 13d-1(c) ☐ Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent]
[FOR RELEASE November 3, 2015 China Biologic Reports Financial Results for the Third Quarter of 2015 3Q15 Total Sales Up 14.4% YoY to $78.8 Million 3Q15 Non-GAAP Net Income Up 23.6% YoY to $26.2 Million 9M15 Total Sales Up 23.2% YoY to $228.2 Million 9M15 Non-GAAP Net Income Up 31.1% YoY to $79.7 Million Raises Forecast for FY15 Non-GAAP Adjusted] []
[FOR RELEASE November 3, 2015 China Biologic Reports Financial Results for the Third Quarter of 2015 3Q15 Total Sales Up 14.4% YoY to $78.8 Million 3Q15 Non-GAAP Net Income Up 23.6% YoY to $26.2 Million 9M15 Total Sales Up 23.2% YoY to $228.2 Million 9M15 Non-GAAP Net Income Up 31.1% YoY to $79.7 Million Raises Forecast for FY15 Non-GAAP Adjusted] []
[] [CERTIFICATIONS I, David (Xiaoying) Gao, certify that: 1. I have reviewed this quarterly report on Form 10-Q of China Biologic Products, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [CERTIFICATIONS I, Ming Yang, certify that: 1. I have reviewed this quarterly report on Form 10-Q of China Biologic Products, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements] [2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. David (Xiaoying) Gao Chief Executive Officer] [2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. Ming Yang Chief Financial Officer (Principal Financial Officer)]
[CUSIP No. 16938C106 1. Names of Reporting Persons 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☐]
[FOR RELEASE October 20, 2015 China Biologic Received Operating Permit for New Branch Collection Facility in Shandong Province BEIJING, China – October 20, 2015 – This new branch collection facility will operate under the Company’s Ningyang plasma collection station and cover the collection territory of Zaozhuang City, which has a population of 3.8 million and offers a reliable source of] []
[FOR RELEASE October 20, 2015 China Biologic Received Operating Permit for New Branch Collection Facility in Shandong Province BEIJING, China – October 20, 2015 – This new branch collection facility will operate under the Company’s Ningyang plasma collection station and cover the collection territory of Zaozhuang City, which has a population of 3.8 million and offers a reliable source of] []
[CUSIP No. 16938C106 1. Names of Reporting Persons 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☐]
[FOR RELEASE September 8, 2015 China Biologic to Build New Branch Collection Facility in Shandong Province BEIJING, China – September 8, 2015 – City, which has a population of 3.8 million and offers a reliable source of plasma donors. As the Company had This new plasma collection facility, located in Shanting District of Zaozhuang City, will be a branch of] []
